- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Spartanburg, South Carolina • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 776
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 227
- States / cities
- Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
- Conditions
- Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Primary Melanocytic Lesion of Meninges, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Therapeutic Conventional Surgery
- Radiation · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Charlottesville, Virginia
- Conditions
- Malignant Glioma
- Interventions
- Carboplatin, Cyclophosphamide, Etoposide Phosphate, Quality-of-Life Assessment, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio • Portland, Oregon
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
- Interventions
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Epilepsy, Cancer, Brain Neoplasm
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 8 Years to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Neoplasms, Adult, Malignant
- Interventions
- Stereotactic Radiosurgery
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
- Interventions
- 131-I-TM-601, 131I-TM601
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Interventions
- Toca 511 vector, Toca FC
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 7 more
- Conditions
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
- Interventions
- Palbociclib, Pembrolizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Tumors, Metastatic Disease
- Interventions
- donepezil hydrochloride, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 16
- States / cities
- Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more
- Conditions
- Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Brain Tumor Not Otherwise Specified, Recurrent Ependymoma
- Interventions
- Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 17
- States / cities
- Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
- Conditions
- Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
- Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol Non-Stoichiometric Magnetite, Gadolinium
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Intracranial Neoplasms, Neoplasm Metastasis
- Interventions
- 2-deoxyglucose (2DG)
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Interventions
- Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
- Interventions
- Steroids, ZD6474
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
- Interventions
- Cytoreductive surgery, Perifosine, Temsirolimus
- Procedure · Drug
- Lead sponsor
- Andrew B Lassman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 3'-deoxy-3'-[18F]fluorothymidine
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer
- Interventions
- temsirolimus, pharmacological study, cytokine levels
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
- Interventions
- propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 12 Months to 60 Months
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin